Suppliers / Piramal Healthcare UK

Piramal Healthcare UK

United Kingdom Updated 9 July 2026

Piramal Healthcare UK is a finished-dose manufacturer based in United Kingdom. It holds 2 active US drug master files and one valid CEP across a filed portfolio of 2 molecules. Its filings concentrate with MINSA (CR), EDE (AE) and NAFDAC (NG). Its GMP standing is certified by MHRA (UK), NAFDAC (NG) and US FDA, among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 30 May 2025 as NAI.

2
active US DMFs
1
valid CEPs
8
registered plants 3 with an FDA FEI number
19
filings across 9 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
3 of 3 confirmed
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 30 May 2025 NAI US FDA
  • 18 March 2022 VAI US FDA
  • 18 June 2021 VAI US FDA
  • 21 September 2018 VAI US FDA
  • 18 May 2018 NAI US FDA
  • 13 January 2017 NAI US FDA
  • 30 January 2015 VAI US FDA
  • 17 October 2014 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Morpeth, United Arab Emirates Not on file
Canada, Canada 3002808377
GRANGEMOUTH, United Kingdom Not on file
Morpeth, United Kingdom Not on file
NORTHUMBERLAND, United Kingdom Not on file
United Kingdom, United Kingdom 3003723155

2 further sites are on record.

What they file, and where

Molecule Regulators Docs
Misoprostol EDQM, US FDA 2
Cloprostenol US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 5 None
EDE (AE) 5 None
NAFDAC (NG) 3 2
NPRA (MY) 1 None
MCAZ (ZW) 1 None
ARCSA (EC) 1 None
MHRA (UK) None 12
US FDA None 1
NCELS (KZ) None 1

Comparing suppliers?

Choose your molecules and target markets. Piramal Healthcare UK comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 30 May 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates